AeroPulsR™ generates aqueous aerosols for respiratory drug delivery, while SUPRAER™ delivers dry respirable aerosols. Both devices are engineered to address limitations of traditional nebulizers and atomizers, with the goal of improving therapeutic aerosol delivery in critical care settings.
A key component of KAER’s platform is its proprietary aerosolizing nozzle, which has been patented in six countries. This nozzle is capable of aerosolizing a wide range of formulations, including biologics, small molecules, genetic payloads, antibiotics, and high-viscosity hydrogels (up to 80 cP). Aerosol particles are consistently delivered in the 2–4 µm range, with adjustable flow rates between 0.5–4 mL/min, optimum for deep lung deposition.
Notably, research studies demonstrated that aerosolized pulmonary surfactant retained its biophysical activity following delivery with KAER’s nozzle technology. These pioneering results using air and heliox were published in the Journal of Aerosol Science and Technology. These findings support the potential of the technology in preserving the integrity of fragile compounds during delivery.
The AeroPulsR™ system is equipped with integrated hardware and software that allows for breath-synchronized delivery, dose customization, and user-friendly programming. Designed for both pediatric and adult patients, it offers continuous, periodic, or spontaneous aerosol generation modes.
During the 2025 scientific meetings, KAER’s CEO Dr. Yeates reported strong interest from aerosol science experts, who noted the device’s potential for delivering controlled doses with minimal waste and high lung deposition efficiency.
Beyond healthcare, KAER is exploring broader applications for its aerosol generation technology, including:
1. Animal health and livestock vaccination
2. Agricultural delivery of fertilizers and herbicides
3. Paints, coatings, and adhesive deposition in manufacturing
4. Cosmetic formulations
5. Robotic or drone-based aerosol dispersal
KAER continues to invite collaborations and inquiries from healthcare and industrial partners. For more information, please visit KAER’s website.
Donovan B Yeates
KAER Biotherpeutics Corporation
+1 760-480-9400
dyeates@kaerbio.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. 